UFT specific use-results survey "Outcome research of patients who enrolled in a NSAS-BC 01 trial or CUBC trial"

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080223266

Enrollment

967

Registered

2016-07-20

Start date

2016-07-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

investigational material(s) Generic name etc : UFT combination capsule T100, UFT E combination granule T100/T150/T200 INN of investigational material : Tegafur,Uracil Therapeutic category code : 422 A

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Among the patients enrolled in NSAS-BC01 study and CUBC study, those who are surviving or lost to follow up at the 5-year survival analysis are included in the surveillance analysis.

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026